This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
HitGen is a rapidly developing biotech company focused on the discovery and development of novel medicines and agrochemicals using world-leading DNA-encoded library (DEL), FBDD/SBDD, protein degradation, and oligonucleotide-based therapeutic platforms.
HitGen Inc. (SSE: 688222.SH) is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK, and Houston, USA. We have established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs.
Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design (FBDD/SBDD), oligonucleotide-based therapeutics (OBT), and targeted protein degradation (TPD). We are also developing a DEL+AI+Automated DMTA platform to accelerate preclinical candidate discovery.
Dr. Jin Li, Founder, Chairman, and CEO of HitGen, honored with the "Jinsha Friendship Award" in Chengdu.
Accelerating drug discovery projects with high efficiency through our comprehensive suite of technologies and services.
Design, synthesis, and screening of libraries containing over 1.2 trillion unique compounds.
Discovery of PROTACs, molecular glues, and evaluation of degrader efficacy.
Fragment-based and structure-based drug design with over 6,000 complex structures solved.
Discover how HitGen’s advanced platforms empower global pharmaceutical innovation.
Creation of ultra-large libraries with >1.2 trillion compounds using proprietary chemistry and encoding strategies.
High-throughput screening against diverse targets using NGS and bioinformatics analysis for hit identification.
Open-access DEL platform enabling collaborative discovery with academic and industry partners.
Custom design of DNA tags and barcodes for DEL and oligonucleotide therapeutics.
Development of novel building blocks and resin systems for DEL and peptide synthesis.
Synthesis of modified and functionalized oligonucleotides for therapeutic and diagnostic applications.
Lipid nanoparticles, conjugates, and other delivery systems for efficient intracellular delivery.
Hit-to-lead and lead optimization using high-throughput synthesis and structure-activity relationship (SAR) studies.
In vitro and in vivo assays for target validation, potency, selectivity, and ADMET profiling.
Custom development and manufacturing for small molecules and oligonucleotides from mg to kg scale.
Protein expression, purification, crystallization, and structural determination for SBDD.
AI/ML-driven molecular design, virtual screening, and DMTA cycle automation.
HitGen has officially submitted its commitment letter to the SBTi, pledging to set near-term science-based targets aligned with the 1.5°C goal of the Paris Agreement. This marks a significant step in our ESG journey.
HitGen was selected as one of the “2024 Top 100 Chinese Pharmaceutical Innovation Enterprises” and Dr. Jin Li honored as one of the “Decade of Innovation - Decade of the Future” leaders.
For more information about our platforms and collaboration opportunities, please reach out through our official channels.
Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact support@fobcompany.info via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系support@fobcompany.info 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact support@fobcompany.info
如果您是其他域名合作 也请联系support@fobcompany.info